Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127471481 | 12747148 | 1 | I | 20160906 | 20160915 | 20160915 | EXP | PHHY2016ES125104 | SANDOZ | VALERA RUBIO M, LABRADOR ANDUJAR N, RUBIO SALVADOR AR, CHACON LOPEZ-MUNIZ JI, DIAZ PANIAGUA L.. PHARMACOLOGICAL APPROACH FOR THE MANAGEMENT OF ADRENOCORTICAL CARCINOMA: A CASE REPORT. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2016;18(3):199-01 | 16.00 | YR | F | Y | 0.00000 | 20160915 | OT | ES | ES |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127471481 | 12747148 | 1 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 50 MG/M2, UNK ON DAY 1 EVERY 21 DAYS | 0 | 50 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 100 MG/M2, UNK, ON DAY 1 | 0 | 100 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 3 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | 50 MG/M2, UNK, DAY 1 | 0 | 50 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 4 | PS | DOXORUBICIN | DOXORUBICIN | 1 | Unknown | 50 MG/M2, UNK ON DAY 1 EVERY 21 DAYS | 200146 | 50 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 5 | SS | DOXORUBICIN | DOXORUBICIN | 1 | 200146 | ||||||||||||
| 127471481 | 12747148 | 6 | SS | DOXORUBICIN | DOXORUBICIN | 1 | 200146 | ||||||||||||
| 127471481 | 12747148 | 7 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | 100 MG/M2, UNK, DAY 1,2,3 EVERY 21 DAYS | 0 | 100 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 8 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 9 | SS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | 800 MG, UNK | 0 | 800 | MG | ||||||||
| 127471481 | 12747148 | 10 | SS | CAPECITABINE. | CAPECITABINE | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 11 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | 800 MG/M2, UNK | 0 | 800 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 12 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 13 | C | SORAFENIB | SORAFENIB | 1 | Unknown | 400 MG, Q12H | 0 | 400 | MG | Q12H | |||||||
| 127471481 | 12747148 | 14 | C | SORAFENIB | SORAFENIB | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 15 | C | SORAFENIB | SORAFENIB | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 16 | C | IFOSFAMIDE. | IFOSFAMIDE | 1 | Unknown | 2000 MG/M2, UNK | 0 | 2000 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 17 | C | IFOSFAMIDE. | IFOSFAMIDE | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 18 | C | MESNA. | MESNA | 1 | Unknown | 2000 MG/M2, UNK ON DAY 1-3 | 0 | 2000 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 19 | C | MESNA. | MESNA | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 20 | C | LIPOSOMAL DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | 20 MG/M2, UNK, ON DAY 1 EVERY 21 DAYS | 0 | 20 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 21 | C | LIPOSOMAL DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | 50 MG/M2, UNK, DAY 1 EVERY 21 DAYS | 0 | 50 | MG/M**2 | ||||||||
| 127471481 | 12747148 | 22 | C | FILGRASTIM | FILGRASTIM | 1 | Unknown | 300 UG | 0 | 300 | UG | ||||||||
| 127471481 | 12747148 | 23 | C | FILGRASTIM | FILGRASTIM | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 24 | C | PACLITAX NAB | PACLITAXEL | 1 | Unknown | 150 MG/M2, QW | 0 | 150 | MG/M**2 | /wk | |||||||
| 127471481 | 12747148 | 25 | C | PEGFILGRASTIM | PEGFILGRASTIM | 1 | Unknown | 0 | |||||||||||
| 127471481 | 12747148 | 26 | C | PEGFILGRASTIM | PEGFILGRASTIM | 1 | 0 | ||||||||||||
| 127471481 | 12747148 | 27 | C | BEVACIZUMAB | BEVACIZUMAB | 1 | Unknown | 15 MG/KG, UNK, EVERY 15 DAYS | 0 | 15 | MG/KG | ||||||||
| 127471481 | 12747148 | 28 | C | ERYTHROPOETIN | ERYTHROPOIETIN | 1 | Unknown | 0 | |||||||||||
| 127471481 | 12747148 | 29 | C | ERYTHROPOETIN | ERYTHROPOIETIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127471481 | 12747148 | 1 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 2 | Metastases to lung |
| 127471481 | 12747148 | 3 | Hepatic lesion |
| 127471481 | 12747148 | 4 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 5 | Metastases to lung |
| 127471481 | 12747148 | 6 | Hepatic lesion |
| 127471481 | 12747148 | 7 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 8 | Metastases to lung |
| 127471481 | 12747148 | 9 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 10 | Metastases to lung |
| 127471481 | 12747148 | 11 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 12 | Metastases to lung |
| 127471481 | 12747148 | 13 | Metastases to liver |
| 127471481 | 12747148 | 14 | Metastases to kidney |
| 127471481 | 12747148 | 15 | Metastases to retroperitoneum |
| 127471481 | 12747148 | 16 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 17 | Metastases to lung |
| 127471481 | 12747148 | 18 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 19 | Metastases to lung |
| 127471481 | 12747148 | 20 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 21 | Metastases to lung |
| 127471481 | 12747148 | 22 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 23 | Metastases to lung |
| 127471481 | 12747148 | 24 | Product used for unknown indication |
| 127471481 | 12747148 | 25 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 26 | Metastases to lung |
| 127471481 | 12747148 | 27 | Product used for unknown indication |
| 127471481 | 12747148 | 28 | Adrenocortical carcinoma |
| 127471481 | 12747148 | 29 | Metastases to lung |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127471481 | 12747148 | OT |
| 127471481 | 12747148 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127471481 | 12747148 | Adrenocortical carcinoma | |
| 127471481 | 12747148 | Disease progression | |
| 127471481 | 12747148 | Gastroenteritis | |
| 127471481 | 12747148 | Intracardiac thrombus | |
| 127471481 | 12747148 | Mucosal inflammation | |
| 127471481 | 12747148 | Pancytopenia | |
| 127471481 | 12747148 | Pneumonia | |
| 127471481 | 12747148 | Pyrexia | |
| 127471481 | 12747148 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127471481 | 12747148 | 3 | 201203 | 0 | ||
| 127471481 | 12747148 | 9 | 201206 | 0 | ||
| 127471481 | 12747148 | 11 | 201206 | 0 | ||
| 127471481 | 12747148 | 13 | 201008 | 201010 | 0 | |
| 127471481 | 12747148 | 16 | 201012 | 0 | ||
| 127471481 | 12747148 | 18 | 201012 | 0 | ||
| 127471481 | 12747148 | 21 | 201203 | 0 |